Bernard Cole

Bernard Cole

Auto-generated profile, based on publicly available information

Bernard Cole

Department of Mathematics and Statistics, University of Vermont, Burlington, VT, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2022 in European Journal of Cancer
Verified
Journal Article
Open access
RGRichard D. Gelber
Richard D. Gelber
XWXin V. Wang
Xin V. Wang
BCBernard F. Cole
Bernard F. Cole
DCDavid Cameron
David Cameron
FCFatima Cardoso
Fatima Cardoso
MPMartine Piccart-Gebhart
Martine Piccart-Gebhart
The APHINITY trial showed that adding adjuvant pertuzumab (P) to trastuzumab and chemotherapy, compared with adding placebo (Pla), significantly improved invasive disease-free survival (IDFS) for patients with HER2+ early breast cancer both overall and for the node-positive (N+) cohort. We explored whether adding P could benefit some N- subpopulations and whether to consider de-escalation for some N+ subpopulations. Subpopulation Treatment Effect Pattern Plot (STEPP) is an exploratory, graphical method that plots estimates of treatment effect for overlapping patient subpopulations defined by a covariate of interest. We used STEPP to estimate Kaplan-Meier differences in 6-year IDFS percentages (P minus Pla: Δ ± standard error [SE]), both overall and by nodal status, for overlapping subpopulations defined by (1) a clinical composite risk score, (2) tumour infiltrating lymphocytes (TILs) percentage, and (3) human epidermal growth factor receptor 2 (HER2) FISH copy number. Because of multiplicity, a Δ of at least three SE is required to warrant attention. The average absolute gains in 6-year IDFS percentages were 2.8 ± 0.9 overall; 4.5 ± 1.2 for N+ and 0.1 ± 1.1 for N-. Largest gains were for patients with intermediate clinical composite risk (5.3 ± 1.9 overall; 6.9 ± 2.3 N+; 4.0 ± 3.0 N-), highest TILs percentage (6.3 ± 1.7 overall; 7.4 ± 2.4 N+; 3.2 ± 1.7 N-), and intermediate HER2 copy number (2.8 ± 1.9 overall; 7.4 ± 2.5 N+; -1.3 ± 1.9 N-), but clear evidence indicating a pattern of differential subpopulation treatment effects was lacking. STEPP plots for N- did not identify subpopulations clearly benefiting from adding P, and those for N+ did not identify subpopulations warranting de-escalation. TILs percentage appeared to be more predictive of P treatment effect than clinical composite risk score. clinicaltrials.gov Identifier NCT01358877.

19 June 2006
Verified
Book
Closed access
PDF file
BCBernard Cole
Bernard Cole
This is the first explanation and evaluation of Taiwan’s defence forces and infrastructure. It examines not only Taiwan’s armed forces, but also its Ministry of National Defence, personnel issues, and civil-military relations. This book provides crucial base-line data and evaluation of one of the major participants in an ongoing crisis across the Taiwan Strait that has the potential of involving China and the United States in armed conflict. It examines the danger of a possibly nuclear conflict between China and the United States which would seriously disrupt all of East Asia. It also shows how Taiwan’s defence policies and actions do not match the threat - Taipei needs to develop and pursue realistic policies. This is essential reading for all students of East Asian security and Sino-American relations and of international and security studies in general.

15 July 2004 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JRJ. R. Rigas
J. R. Rigas
MCM. Carey
M. Carey
BCB. Cole
B. Cole
AEA. Evans
A. Evans
RPR. Page
R. Page
KDK. Dragnev
K. Dragnev
7071 Background: For patients (pts) with advanced disease and a good performance status (PS) PB therapy is recommended. To date, the survival benefit of a NPB remains unanswered. This trial is designed to compare the overall survival (OS) of NPB vs PB therapy for advanced NSCLC testing for equivalence. Methods: Pt eligibility: pathological stage IIIB/IV NSCLC, PS 0–2, and no prior chemotherapy. Randomized pts were stratified by stage and PS to arm A: carboplatin AUC = 6 + docetaxel 75 mg/m2 every 3 wks (PB) or arm B: gemcitabine 1 gm/m2 + docetaxel 40 mg/m2 days 1 and 8 every 3 wks (NPB). The primary endpoint is OS. Relative risk (RR) and log-rank will be used to establish therapeutic equivalence (RR 0.8–1.2). Planned sample size 928 pts. This trial is monitored by an independent SDMC and source documentation (SD) for all web-based entries is sought. Results: As of December 2003, 732 pts (367 pts arm A vs 365 pts arm B) are enrolled at 87 sites. Pt characteristics are balanced for gender (38% female), age (median 65, range 36–90), PS (14% PS2), stage (76% stage IV) and histology (51% adenocarcinoma, 20% squamous cell). Arm A received 1,538 cycles and 1,335 cycles in arm B. Serious adverse events (SAEs) occurred 135 pts in arm A and 184 in arm B. Only 30% of all SAEs are attributed to therapy. There were 2 treatment-related deaths, one on each arm. In July 2003 at a predefined interim analysis with 97% of the data SD, 250 deaths occurred among 620 randomized pts. The OS yielded p = 0.38. The 1-year survival rate was 45% for PB and 42% for NPB. The pre-specified stopping rule for superiority was p = 0.01. The SDMC recommended continuation. We anticipate completion by May 2004 and presentation of the final data sets in June 2004. Conclusions: At the predefined interim analysis, there appears to be no statistical survival advantage for platinum or non-platinum-based therapy. At present, there appear to be qualitative and quantitative differences in SAEs. Upon completion, we will definitively comment on the equivalence of a non-platinum-based treatment for this disease.

20 June 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SKS. L. Ketchum
S. L. Ketchum
BCB. Cole
B. Cole
KMKim allyson Margolin
Kim allyson Margolin
DMD. McDermott
D. McDermott
TCT. Crocenzi
T. Crocenzi
MEMarc S Ernstoff
Marc S Ernstoff
8034 Background: Lymphocyte depletion followed by homeostatic recovery has been shown to break tumor-specific tolerance. We have initiated a clinical trial of chemotherapy-induced lymphodepletion followed by high-dose (HD) IL-2 + GM-CSF in metastatic melanoma (MM) patients (pts). Methods: Pts with PS 0–1, normal organ function and with measurable MM were treated with intravenous cyclophosphamide 60 mg/kg (day 1–2), fludarabine 25 mg/m2 (day 3–7) followed by two 5-day (d) courses of intravenous HD bolus IL-2 600,000 IU/kg (d 8–12 and 21–25) and daily subcutaneous administration of GM-CSF 250 mcg/m2 (d 8 until granulocyte recovery). Results: 8 pts are presently evaluable in this first stage of accrual to confirm safety and immunomodulation. A mean of 25/28 IL-2 doses were delivered. All pts experienced transient myelosuppression with ANC < 500 cells/mm3 for a median of 7d (range 5–11d) and platelets <50,000/mm3 for a median of 5.5 days (range 0–7d). Pts exhibited reversible capillary leak associated with high-dose IL-2. With the exception of myelosuppression, no grade 4 toxicities occurred. All pts experienced neutropenic fever and 2 developed line infections. CD4+/CD25high/CD62L+ T cells rebounded by d 14, peaked around d 28 and returned to baseline by d 85. CD8+/CD28- T cells recovered to levels lower than baseline for the first 28d but then showed persistent elevation through d 113. Skewing of T-cell populations based on TCR β chain expression was observed. One pt achieved complete response, 2 achieved partial responses, and 5 progressed. Conclusions: Lymphodepletion followed by high-dose IL-2 can be safely administered, affects immune reconstitution, and has activity in MM that may be useful as a platform for enhancing immunotherapeutic strategies. The trial continues to accrue in order to better estimate antitumor activity and immunomodulation. No significant financial relationships to disclose.

1 July 2021 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
CKC. Matthew Kinsey
C. Matthew Kinsey
EBEhab Billatos
Ehab Billatos
VMVitor Mori
Vitor Mori
BTBen Tonelli
Ben Tonelli
BCBernard F. Cole
Bernard F. Cole
RERaúl San José Estépar
Raúl San José Estépar
A simple assessment of lung nodule location for reduction in unnecessary invasive procedures C. Matthew Kinsey, Ehab Billatos, Vitor Mori, Ben Tonelli, Bernard F. Cole, Fenghai Duan, Helga Marques, Isaac de la Bruere, Jorge Onieva, Rubén San José Estépar, Alyx Cleveland, Dan Idelkope, Chris Stevenson, Jason H. T. Bates, Denise Aberle, Avi Spira, George Washko, Raúl San José Estépar